Therapeutics

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microfluidics #Oncology #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Target validation #Therapeutics #Toxicology

The Current Bioinformatics Analytical Software Landscape

The Current Bioinformatics Analytical Software Landscape By Charles Chang With the vast amount of biochemical data generated from experiments conducted by research laboratories around the globe, there is strong demand for software to analyse and manage the data effectively. Analytical software can be utilised to analyse virtually every single experiment,… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmacology #Pharmokinetics #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics

Virtual Screening – Finding needles in a haystack on a shoestring

Virtual Screening - Finding needles in a haystack on a shoestring By Dr David E. Clark, Neil V. Harris, Alan G. Roach and Dr Anthony D. Baxter In recent years, virtual screening (VS) has become an accepted approach to hit-finding alongside biochemical high-throughput screening (HTS). Large pharmaceutical companies are typically… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Business #Chemical engineering #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microfluidics #Molecular medicine #Patent Law #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Tools for Structural Genomics – Accelerating the structure pipeline

Share Share Tweet Email Tools for Structural Genomics - Accelerating the structure pipeline Tools for Structural Genomics - Accelerating the structure pipeline By Dr Lawrence J. DeLucas, Dr Christie G. Brouillette, Dr Kal Ramnarayan and Dr Shankari Mylvaganam The international structural genomics effort has resulted in a number of technological… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Organic chemistry #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

Opportunities for the pharmaceutical industry: key biotransformation technologies of the future

Opportunities for the pharmaceutical industry: key biotransformation technologies of the future By Praveen Kaul, Anirban Banerjee and Professor UC Banerjee Biotransformation is a broad and growing field of biotechnology and encompasses both enzymatic and microbial biocatalysis. Progress has been made in research on the key drivers of biotransformations, including the… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #Lead discovery #Protein chemistry / Proteomics #Sequencing #Therapeutics

Drug Discovery Spending – A Year In Review

Drug Discovery Spending - A Year In Review By Isaac Meek Drug In 2003, the research products market reported revenues of $23 billion, with a 7.5% growth rate over 2002. Although there are many consumers in this market, by far the greatest are drug discovery research groups. In recent history,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Target validation #Therapeutics #Toxicology

Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library

Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library By Andrea Kroenke, Anne Grabner, Dr Michael Hannus, Dr Christoph Sachse, Dr David Dorris and Dr Christophe Echeverri Libraries of siRNAs directed against predefined subsets of genes now offer the capacity to greatly accelerate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Pathology #Stem cells #System biology #Therapeutics #Toxicology

Protease Inhibitor Therapeutics for Respiratory Disease

Protease Inhibitor Therapeutics for Respiratory Disease By Dr Philip J. Barr Disruption of the natural equilibria between proteases and their cognate inhibitors is a common feature of inflammatory disease. When this occurs in the lung, the effects can lead to irreversible impairment of pulmonary function. Although protease inhibition has been… Read More

#Archive

#Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Preclinical #Regulatory #Sequencing #System biology #Systems biology #Theranostics #Therapeutics

Fewer drugs approved, more money spent – Where’s the beef?

Fewer drugs approved, more money spent - Where's the beef? By G. Steven Burrill Three years ago, when biotech was at its Wall Street heights, personalised medicine and its promise were on everyone's lips. Billions of dollars were being put to work to make targeted medicine a reality... and genomics… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Automation / robotics #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Lead discovery #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Target validation #Therapeutics

Urinary troubles for more than the ageing

Urinary troubles for more than the ageing By Dr Anthony PDW Ford The needs of younger incontinence sufferers coupled with the ageing of the baby-boomer population portend a big boost in demand for effective and well tolerated new medicines for lower urinary-tract dysfunction. This market is under-served today, presenting a… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Protein BIOMARKER Strategies

By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #System biology #Systems biology #Therapeutics

The cost and value of three-dimensional protein structure

The cost and value of three-dimensional protein structure By Professor Raymond C. Stevens During the past few years we have seen the cost of protein three-dimensional structure determination begin to converge by protein family type, there has been a commoditisation of high-throughput structure based drug discovery technology components, and the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Molecular pathology and the art of drug design

Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Mass spectrometry / NMR #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The Protein Biochip Content Problem

The Protein Biochip Content Problem By Dr Steven Bodovitz The protein biochip industry has a content problem that is not only slowing its development as a whole but possibly the development of the entire proteomics industry. In science, for a problem to have its own name, it needs to be… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

RNA interference – A technology platform for target validation, drug discovery and therapeutic development

RNA interference - A technology platform for target validation, drug discovery and therapeutic development By Dr Krishnarao Appasani In the post genomic era, elucidation of the physiological function of genes has become a major rate-limiting step in the quest to develop 'gene-based-drugs'. As we advance in the 'functional omics' arena… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Immunology #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Organic chemistry #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Functional proteomics in drug discovery

Functional proteomics in drug discovery By Dr Stefan W. Henning and Dr Leodevico L. Ilag The critical bottleneck of the drug discovery process is developing the right drug for the right target. Today proteins represent more than 90% of druggable targets and will most likely remain the single most important… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Pathology #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Target validation #Therapeutics

The role of ZEBRAFISH in drug discovery

The role of ZEBRAFISH in drug discovery By Dr Paul Goldsmith and Roberto Solari The NIH has ranked the Zebrafish as the third most important experimental organism after man, the Sanger Centre is sequencing the genome and many medical researchers are shifting over to it. But will the zebrafish have… Read More

#Archive